The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model
Katharine V. Jensen(University of Calgary), H. Artee Luchman(University of Calgary)
Cited by 68
Related Papers
EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo
|Neuro-Oncology Advances|2020|24
Prostate Epithelium-Specific Deletion of the Selenocysteine tRNA Gene Trsp Leads to Early Onset Intraepithelial Neoplasia
|American Journal Of Pathology|2014|18